Skip to content

Urinary T Cell Biomarker for Prediction in ANCA Glomerulonephritis

Phenotype of Urinary CD4+ T Cells as Biomarkers for Prediction of Outcome in ANCA Glomerulonephritis

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04320667
Enrollment
79
Registered
2020-03-25
Start date
2019-11-19
Completion date
2022-12-31
Last updated
2022-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glomerulonephritis Acute

Keywords

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Pauci-Immune Vasculitis, Churg-Strauss Syndrome, Granulomatosis with Polyangiitis, Microscopic Polyangiitis, urinary biomarker, outcome, prediction,, urinary effector memory T lymphocytes, glomerulonephritis, non-invasive biomarker, flow cytometry, treatment outcome, CD4-Positive T-Lymphocytes/immunology

Brief summary

Urinary T lymphocytes may be predictive for clinical outcome in patients with ANCA associated glomerulonephritis (ANCA GN). The investigators hypothesize that the amount of CD4+ effector/memory T cells in urine at time of diagnosis predicts the outcome of patients with active ANCA GN after 6 months of therapy. In a prospective, six-months follow-up study patients' urine will be analysed by flow cytometry every 60 days (+/- 10d). Treatment will be performed to the discretion of the treating clinician. After 6 months of treatment response will be determined as either complete response or partial response.

Interventions

Urine samples will be conserved and frozen upon arrival. All samples will be stained according to T cell and TEC (tubular epithelial cells) panel with fluorochromes. T cell panel: CD3, CD4, CD8, CCR7, CD45RO, CD28, CD279; TEC panel: vimentin, cytokeratine, CD10, CD13, CD227, CD326

Sponsors

Berlin Institute of Health
CollaboratorOTHER
Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Informed consent * Biopsy proven ANCA related glomerulonephritis * In absence of biopsy clinical diagnosis of ANCA related glomerulonephritis

Exclusion criteria

* Biopsy proven non-ANCA related kidney disease * Active menstrual bleeding * Urinary tract infection * Kidney transplantation during observational period

Design outcomes

Primary

MeasureTime frameDescription
Phenotype of CD4+ T cells at time point 0 predictive of clinical outcome in patients with active ANCA-assosciated glomerulonephritis6 monthsUrinary CD4+ effector/memory T cell counts at time point 0 (time of diagnosis) predict clinical outcome (complete or partial response) after 6 months of treatment in patients with active ANCA-assosciated glomerulonephritis. The frequency of effector/memory CD4+ T lymphocytes is higher in patients with non- or partial response. Complete response at 24 weeks: BVAS = 0 Partial response at 24 weeks: at least one renal element of the BVAS score.

Secondary

MeasureTime frameDescription
Analysis of patients with persistent renal abnormalities as partial response6 months
Phenotype of CD8+ T cells at time point 0 predictive of clinical outcome in patients with active ANCA-assosciated glomerulonephritis6 monthsUrinary CD8+ effector/memory T cell counts at time point 0 (time of diagnosis) predict clinical outcome (complete or partial response) after 6 months of treatment in patients with active ANCA-assosciated glomerulonephritis. The frequency of effector/memory CD8+ T lymphocytes is higher in patients with non- or partial response.
Subgroup analysis according to treatment6 months
Diagnosis of active glomerulonephritis in Patients with ANCA associated vasculitis6 monthsDiagnosis according to initial T cell count
Prediction of complete or partial response according to normalization of the amount of urinary T cells at time point 2 and 46 months

Countries

Germany, United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026